Granted Patent
B2
US 12,378,232 · App. 17/544,303 · Granted Aug 5, 2025
Cyclin dependent kinase inhibitors
Inventors:
Ping Chen (San Diego, CA); Sujin Cho-Schultz (San Diego, CA); Judith Gail Deal (San Diego, CA); Gary Michael Gallego (San Diego, CA); Mehran Jalaie (San Diego, CA); Robert Steven Kania (Del Mar, CA); Sajiv Krishnan Nair (San Diego, CA); Sacha Ninkovic (San Diego, CA); Suvi Tuula Marjukka Orr (San Diego, CA); Cynthia Louise Palmer (La Mesa, CA)
Assignee:
Pfizer Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R 1 to R 23 , A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
Claims (2)
1. A compound, which is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol, wherein one or more hydrogen atoms are replaced by deuterium.
2. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
Assignments (1)
ASSIGNEE ADDRESS CORRECTION
Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →